Evidence map›Paper›PMID 21423795›Full record

ArticlePloS one2011

Rare and frequent promoter methylation, respectively, of TSHZ2 and 3 genes that are both downregulated in expression in breast and prostate cancers.

Miyako Yamamoto, Emili Cid, Samuel Bru, Fumiichiro Yamamoto

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

  • Commented on by
5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Miyako YamamotoBurnham Institute for Medical Research, La Jolla, California, United States of America. fyamamoto@imppc.org
Emili Cid
Samuel Bru
Fumiichiro Yamamoto
Institute of Predictive and Personalized Medicine of Cancer · ES

Funding

Epigenetic Alterations in Homeotic GenesR01CA087069 · NCI · BURNHAM INSTITUTE FOR MEDICAL RESEARCH · PI YAMAMOTO, FUMIICHIRO · 2002 to 2005
$1.3M
NCI NIH HHS 1R01CA087069NCI NIH HHS R01 CA087069
6 · The paper itself

Abstract

backgroundNeoplastic cells harbor both hypomethylated and hypermethylated regions of DNA. Whereas hypomethylation is found mainly in repeat sequences, regional hypermethylation has been linked to the transcriptional silencing of certain tumor suppressor genes. We attempted to search for candidate genes involved in breast/prostate carcinogenesis, using the criteria that they should be expressed in primary cultures of normal breast/prostate epithelial cells but are frequently downregulated in breast/prostate cancer cell lines and that their promoters are hypermethylated. METHODOLOGY/PRINCIPAL

findingsWe identified several dozens of candidates among 194 homeobox and related genes using Systematic Multiplex RT-PCR and among 23,000 known genes and 23,000 other expressed sequences in the human genome by DNA microarray hybridization. An additional examination, by real-time qRT-PCR of clinical specimens of breast cancer, further narrowed the list of the candidates. Among them, the most frequently downregulated genes in tumors were NP_775756 and ZNF537, from the homeobox gene search and the genome-wide search, respectively. To our surprise, we later discovered that these genes belong to the same gene family, the 3-member Teashirt family, bearing the new names of TSHZ2 and TSHZ3. We subsequently determined the methylation status of their gene promoters. The TSHZ3 gene promoter was found to be methylated in all the breast/prostate cancer cell lines and some of the breast cancer clinical specimens analyzed. The TSHZ2 gene promoter, on the other hand, was unmethylated except for the MDA-MB-231 breast cancer cell line. The TSHZ1 gene was always expressed, and its promoter was unmethylated in all cases. CONCLUSIONS/SIGNIFICANCE: TSHZ2 and TSHZ3 genes turned out to be the most interesting candidates for novel tumor suppressor genes. Expression of both genes is downregulated. However, differential promoter methylation suggests the existence of distinctive mechanisms of transcriptional inactivation for these genes.

Indexed as

Gene Expression Regulation, NeoplasticGenes, Tumor SuppressorPromoter Regions, GeneticBreast NeoplasmsCell Line, TumorDNA MethylationDown-RegulationFemaleGenes, NeoplasmHomeodomain ProteinsHumansMaleOligonucleotide Array Sequence AnalysisProstatic NeoplasmsReverse Transcriptase Polymerase Chain ReactionTranscription FactorsHomeodomain ProteinsTranscription Factors

Identifiers

PMID21423795
PMCPMC3056709
OpenAlexW1967099167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.